A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rachel J. Cook, Eytan Stein, David P. Steensma, Mikkael A. Sekeres, Dale L. Bixby, David Rizzieri, Joseph G. Jurcic, Carlos Enrique Vigil, Robert Redner, Gail J. Roboz, Michael R. Savona, Michael R. McKeown, Kristin Stephens, David A. Roth, Jorge E. Cortes
Institutions: Oregon Health & Science University, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University of Michigan, Duke Medical Center, Columbia University Irving Medical Center, University of Iowa, UPMC Hillman Cancer Center, NewYork–Presbyterian Hospital, Vanderbilt University Medical Center, Syros Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2892218010